Published in final edited form as:

Mol Cancer Res. 2011 November ; 9(11): 1443–1448. doi:10.1158/1541-7786.MCR-11-0322.

The causal link between microsatellite instability and hMRE11 dysfunction in human cancers

XILING WU, YANG XU, WEIHANG CHAI, and CHENGTAO HER*

School of Molecular Biosciences Mail Drop 64-7520 Washington State University Pullman, WA 99164-4660

Abstract

Maintenance of genomic integrity is essential for cell survival, and genomic instability is a commonly recognized intrinsic property of all cancers. Microsatellite instability (MSI) represents a frequently occurring and easily traceable simple form of sequence variation signified by the contraction or expansion of specific DNA sequences containing short tandem repeats. MSI is frequently detected in tumor cells with DNA mismatch repair (MMR) deficiency. It is commonly conceived that instability at individual microsatellite loci can arise spontaneously in cells independent of MMR status, and different microsatellite loci are generally not affected uniformly by MMR deficiency. It is well recognized that MMR deficiency *per se* is not sufficient to initiate tumorigenesis; rather the biological effects have to be exerted by mutations in genes controlling cell survival, DNA damage response, and apoptosis. Recently, shortening of an intronic hMRE11 poly(T)11 tract has been associated with MMR deficiency, raising the possibility that hMRE11 may be inactivated by defective MMR. However, the molecular nature underlying this association is presently unknown, and review of the current literature suggests that hMRE11 is most likely involved with the MMR pathway in a more complex fashion than just being a MMR target gene. An alternative scenario is proposed to better reconcile the differences among various studies. The potential role of hMRE11 in telomere repeats stability is also discussed.

Keywords

Microsatellite instability (MSI); DNA mismatch repair (MMR); DNA repair; DNA damage response; hMLH1; hMRE11

Introduction

Microsatellites are simple tandem nucleotide repeats—reiterated motifs of one to six nucleotides—that are widespread in the human genome (1). Microsatellite instability (MSI) was initially coined to describe a form of DNA aberration involved with expansion or contraction of short nucleotide tandem repeats in colorectal cancers (2-4). Although sporadic MSI can occur in normal cells at various loci at a low frequency, the extent of instability can be elevated by several orders of magnitude in cells with DNA mismatch repair (MMR) deficiency (5). MSI, in varying frequencies, is often observed in tumors of Lynch syndrome (known previously as hereditary non-polyposis colorectal cancer or HNPCC) patients (2-4). On the basis of the Bethesda Guidelines and subsequent revisions (6, 7), a reference microsatellites panel, consisting of both mononucleotide and dinucleotide repeats, and guidelines for MSI testing have been established, by which tumors can be characterized as

*Address all correspondence and reprint requests to: Dr. Chengtao Her at above address. Telephone: (509) 335-7537 Fax#: (509) 335-9688 cher@wsu.edu.

MSI high (MSI-H), MSI low (MSI-L), and microsatellite stable (MSS). Besides being a marker for nucleotide repeats instability, the MSI-H status has also been associated with better prognosis in certain colorectal, gastric, and pancreatic cancers (8). However, for many other malignancies, the correlation between MSI and prognosis remains unclear.

The maintenance of microsatellite repeats integrity in the genome is provided by the MMR system, which corrects single base-base mismatches and insertion/deletion loops (IDLs) on the nascent DNA strand. It is generally accepted that MSI is largely attributable to the failure of repairing IDLs arising from replication slippage. MutS α (hMSH2-hMSH6) recognizes base-base mismatches and small IDLs, whereas MutS β (hMSH2-hMSH3) recognizes IDLs of three or more nucleotides (9, 10). Upon binding, MutS α (or MutS β) undergoes ATP-dependent configuration change conducive for assembly of downstream repair factors including MutL α (hMLH1-hPMS2 heterodimer), the main MutL activity, or one of the minor MutL factors, *i.e.* MutL β and MutL γ (11, 12). The most frequently mutated MMR genes in Lynch syndrome are *hMSH2* and *hMLH1* with incident rates of 39.5% and 59.2%, respectively (www.insight-group.org) (13).

Unlike hMSH2, which is required for all *in vitro* and *in vivo* MMR reactions, MutL α is only required for the *in vitro* MMR reaction in the 3'→5' orientation (14). Intriguingly, a single 5'→3' exonuclease hExo1 has been shown to support *in vitro* MMR in both 5'→3' and 3'→5' orientations (15), of which the action of hExo1 in 3'→5' MMR requires the endonuclease activity carried by MutL α (14). However, *Exo1* deficient mice only display moderate phenotypes in comparison to *Msh2* or *Mlh1* deficient animals (16). In addition, cells lacking *Exo1* are proficient in repairing IDLs of two or more nucleotides (16)—implying the presence of *Exo1*-independent exonuclease activities for the maintenance of microsatellite repeats stability. By interaction with hMLH1, the 3'→5' exonuclease hMRE11 is shown to play a role in the 3'→5' MMR reaction, and RNAi-mediated hMRE11 silencing elevates MSI (17). Current evidence indicates that hMRE11 dysfunction is causally linked to MSI in colon cancers (18-27).

hMRE11 is functionally associated with the MMR protein hMLH1

There are several lines of evidence supporting a direct association of hMRE11 with the MMR machinery. The first indication came when mass spectrometry based analysis revealed that hMRE11 and several MMR proteins coexisted with BRCA1 in a common protein complex referred as BASC (*i.e.* BRCA1-associated genome surveillance complex), which is suggested to function as a DNA damage sensor and to play a broad role in the maintenance of genomic stability (28). The more direct evidence came from studies revealing physical interaction between hMRE11 and hMLH1 through *in vitro* and *in vivo* approaches (17, 29). The hMRE11 and hMLH1 genes also share similar expression profiles in 68 pairs of matched human normal and tumor samples representing 11 tissue types (kidney, breast, prostate, uterus, ovary, cervix, colon, lung, stomach, rectum, and small intestine) and nine cancer cell lines (29), attesting a high likelihood for them to act in common cellular processes.

Studies have shown that the hMRE11-hMLH1 interaction is involved in MMR and DNA damage response to anti-cancer agents (17, 30, 31). RNAi-mediated hMRE11 silencing in HeLa cells led to MSI and defective MMR (17), of which hMRE11 deficiency specifically decreased 3'→5' MMR activity to approximately 50% of the normal (17)—in line with hMRE11 being a 3'→5' exonuclease—and the remaining 50% of 3'→5' MMR activity could be provided by hExo1 (14). The participation of hMRE11 in 3'→5' MMR is likely mediated through its interaction with hMLH1. To this end, expression of hMRE11 aa452-634 polypeptide (*i.e.* the minimal hMLH1 interacting domain) in hMLH1-

complemented MMR proficient 293T cells decreased the efficiency of 3'→5' MMR along with a comparable reduction of the 3'→5' excision activity (31). Intriguingly, the majority of the 38 hMLH1 Lynch syndrome associated missense mutations, representing 25% of approximately 300 known hMLH1 Lynch syndrome mutations, caused significant (>50%) reduction in hMRE11 interaction (31).

Both hMLH1 and the hMRE11 complex are known to play critical roles in mediating cellular DNA damage response. The hMRE11 complex is among the first to arrive at the site of DNA double-strand break (DSB)—sensing of DSB by the hMRE11 complex is required for ATM activation leading to subsequent phosphorylation of a series of downstream effectors to facilitate DNA repair and cell-cycle checkpoint control (32). Likewise, hMLH1 deficiency alters cell cycle regulation in response to DNA damage induced by alkylating agents and cisplatin, thereby renders cells resistant to anticancer treatments (33). These observations raised a possibility that, by virtue of their physical interaction (17, 29), hMRE11 acts with hMLH1 in the same DNA damage-signaling network. The role of hMRE11 in hMLH1-dependent DNA damage response has been studied in cellular responses to alkylating agents and cisplatin (30, 31). The formation of hMRE11 foci in human glioblastoma U87 cells treated with temozolomide (*i.e.* clinical analog of the model alkylating agent MNNG) required intact MMR; silencing of hMLH1 greatly decreased temozolomide-triggered G2 arrest as well as suppressed hMRE11 foci formation (30). Vice versa, RNAi-mediated hMRE11 silencing phenocopied hMLH1 deficiency—both showed reduced temozolomide-triggered G2 arrest and cytotoxicity (30). Furthermore, blocking hMRE11-hMLH1 interaction with hMRE11 aa452-634 polypeptide sufficiently reduced G2 arrest and cytotoxicity in cells treated with MNU or cisplatin (31). Possibly, the hMRE11-hMLH1 interaction exerts its action on DNA damage response through recognition of DNA lesion-containing chromatin. The study by Mirzoeva *et al* suggested that temozolomide could elicit NBS1 and hMLH1 chromatin association (30).

The hMRE11-hMLH1 interaction may also play a role in the regulation of pathway selection during DSB repair. It is known that hMRE11 promotes DSB repair through nonhomologous end-joining (NHEJ) (34, 35), whereas hMLH1 negatively regulates homologous recombination (HR) (36). Thus, the hMRE11-hMLH1 interaction is expected to exert a suppressive effect on homologous recombination through its NHEJ-promoting action.

hMRE11 poly(T)11 mutation in MMR-deficient cancer cells

It is articulated that MMR deficiency *per se* is not sufficient enough to produce profound biological consequences, *e.g.* increasing the risk of cancer. MMR maintains genomic stability through recognition and repair of postreplicative errors that occur at a frequency of one for every 10 million replicated nucleotides (37). This rate of genome alteration is too low to account for the level of genomic instability conducive of Lynch syndrome development in MMR deficient patients. It is believed that MMR defects have to first create mutations in genes that are critical for maintaining genomic stability and proper DNA damage signaling. To this end, 32 putative MMR “target” genes have been identified, of which all genes show instability of coding mononucleotide repeats in MMR deficient cancer cells (38). This target list currently only features genes possessing mononucleotide repeats within protein coding sequences—which include cell cycle and apoptosis regulatory genes (*e.g.* TGFβR2, TCF-4, IGF2R, CDX2, BAX, CASPASE 5, RIZ, FAS, APAF) and genes involved in DNA repair and damage response (*e.g.* MBD4, BLM, CHK1, hMLH1, hRAD50, hMSH3, MSH6). Although the precise pathogenic effects of many coding mononucleotide repeat instability have yet to be explored, these mutations are expected to lead to complete gene inactivation, hence impairing their corresponding pathways.

In contrast to coding mononucleotide repeats instability, appreciation of the effects of non-coding mononucleotide repeats mutations is much more complicated due to the fact that this type of instability is often confounded by incomplete penetrance. Studies in the past several years have revealed a close association of MMR deficiency with mutations of an intronic poly(T)11 repeat in hMRE11 IVS-4 (18-27). This repeat is located one nucleotide upstream of the splicing acceptor sequence at the 3'-end of hMRE11 intron 4. Deletions of 1-2 nucleotides at the poly(T)11 repeats occurred with variable frequencies in MMR-deficient tumors, including colorectal, gastric, endometrial, and urothelial cancer. The frequency of this mutation in MMR-deficient tumors ranges from 67% to 100% for colorectal cancer (18, 21, 24-26), 75% to 92% for stomach cancer (19, 26), 50% to 60% for endometrial cancer (21, 26), and 46% to 75% for urothelial cell carcinomas (22, 26). In addition, the hMRE11 poly(T)11 mutation was common among MMR-deficient/MSI positive tumor cell lines (*i.e.* colorectal, endometrial, prostate, pancreatic, and leukemia/lymphoma) (20, 23, 39). In fact, it appeared that mutations occurred more frequently at the hMRE11 intronic poly(T)11 than the hRAD50 exon 13 poly(A)9 tract in tumor cell lines (20). On the contrary, the (A)7 tract in NBS1 was rarely mutated in MSI-positive gastrointestinal carcinomas (40).

Although the functional consequence of hMRE11 poly(T)11 deletion has yet to be mechanistically addressed, it is shown that deletion of 2 nucleotides in the poly(T)11 repeats increases aberrant splicing and thus correlates with the reduction but not abolition of hMRE11 protein expression (18, 21, 39). Shortening of the poly(T)11 tract may interfere with the recognition of splicing signals and thus promotes aberrant alternative splicing—especially exon 5 skipping (18). The extent of this event appeared to correlate with the size of poly(T)11 deletion, in which significant reduction of hMRE11 protein expression in MMR-deficient tumors is generally associated with bi-allelic 2 bp deletion (21). However, most of the poly(T)11 mutations identified in MMR-deficient tumors are mono-allelic heterozygous with 1 bp deletion (18-26). In MSI-H tumors and cell lines, the incidence of 2 bp deletion at the poly(T)11 tract is much less prevalent than that of the 1 bp deletion (18, 20, 23), suggesting that 2 bp and 1 bp shortening of the poly(T)11 tract are differentially regulated. But it is presently unknown how hMRE11 poly(T)11 mutation is mechanistically controlled by MMR deficiency. In contrast to the frequent frame shift deletion/insertion mutations at the hRAD50 exon 13 poly(A)9 tract (20), the size of hMRE11 poly(T)11 deletions rarely exceeds 2 bp even on an MSI-H background.

It would be of interest to know what maintains the stability after 2 bp deletion, and how MMR deficiency temporally correlates with the occurrence of hMRE11 poly(T)11 mutation during cancer development. Resolution of this conundrum is especially important for a better understanding of the role of MMR-dependent hMRE11 poly(T)11 mutation in genomic instability during cancer development. In addition, it will also help us to devise more effective strategies in cancer therapy. For example, MMR-deficient tumor cells that contain mutations at the hMRE11 poly(T)11 tract are very sensitive to the combined camptothecin/thymidine treatment (41).

hMRE11 dysfunction and microsatellite instability/MMR deficiency

The apparent association of hMRE11 poly(T)11 mutation with MMR deficiency in various tumor types appears to support a scenario that defective MMR could exert its effect on genomic instability by targeting hMRE11 (18, 21). However, the type of poly(T) mutation constituting most of this association is the 1 bp deletion. The overall mutation rate at the hMRE11 poly(T)11 tract was dramatically elevated in MMR-deficient cells but in a cell type specific manner, and colorectal cancer displays by far the highest poly(T)11 mutation rate when both 1 and 2 bp deletions were considered (18, 21, 23, 26). Unfortunately, detection of subtle effects of poly(T)11 deletion on hMRE11 impairment is limited by the sensitivity of

current available techniques, and it is further confounded by the existence of other factors affecting the levels of hMRE11 such as the levels of its binding partner hRAD50. In fact, the lack of a significant correlation between hMRE11 poly(T)11 and hRAD50 exon 13 poly(A)9 mutations and their corresponding protein expression was noted in 27 MSI-H colorectal carcinomas, despite the presence of hMRE11 poly(T)11 mutation in most of the tumors (24). Examination of 10 MMR-deficient cell lines, derived from uterine, endometrial, prostate, and colorectal cancers, revealed that all cell lines contained 1 bp or 2 bp deletion at the hMRE11 poly(T)11 tract but 2 bp bi-allelic deletion was only found in one cell line (20).

Furthermore, current evidence tend to suggest that the causal link between MSI and hMRE11 poly(T)11 mutation is cell type specific. A disconnection between MSI and hMRE11 poly(T)11 mutation was observed in a series of leukemia/lymphoma cell lines (23). Our sequencing analysis of the hMRE11 poly(T)11 tract in MMR-deficient 293T, MMR-proficient 293TL α (33), and HeLa cells identified mono-allelic 1 bp deletion in 293T and mono-allelic 2 bp deletion in 293TL α cells, conversely no mutation was found in HeLa cells. The level of hMRE11 expression in 293T cells was equivalent to that of HeLa cells and it was at least 3 fold higher than that of 293TL α cells. These examples highlight that MMR deficiency is not the major determining factor for hMRE11 impairment. A similar conclusion was drawn when Kern and colleagues analyzed MMR-deficient gastrointestinal cancer cell lines and xenografts—though shortening of hMRE11 poly(T)11 tract was noted, significant reduction of hMRE11 protein expression was not observed (39). Furthermore, Peltomaki and colleagues have recently reported that deletion at the hMRE11 poly(T)11 tract occurred rarely in brain and kidney tumors of MMR-deficient Lynch syndrome patients (26). These evidence are compatible with the inclination that mutations, predominantly 1 bp deletions, at the hMRE11 poly(T)11 tract accumulate in MMR-deficient tumors in a cell type specific manner.

Collectively, aforementioned examples support the view that hMRE11 is unlikely a critical MMR target gene. Given that changes in microsatellites often arise from replication slippage with an estimated frequency of one in every 1000 to 10000 cell divisions (1, 5), 1 bp deletion at the hMRE11 poly(T)11 tract could occur first and later subjected to clonal expansion during malignant transformation. The slight reduction of hMRE11 protein or the expression of low level truncated hMRE11 could potentially render cells susceptible to the risk of disarming the wildtype copy of the concerned MMR genes, therefore converting cells to a MSI-H phenotype and promote mutations in the coding mononucleotide repeats in various MMR target genes (*e.g.* hMSH3, hMSH6, hRAD50, *etc*) (Fig. 1). Together, the overall effect of these mutations could lead to gross genomic alterations required for developing full-blown cancers.

The 2 bp deletion is possibly attributable to MMR deficiency, however, it is unclear whether this deletion derived directly from the wildtype poly(T)11 tract or the 1 bp deletion mutant. Nevertheless, the 2 bp deletion at the hMRE11 (T)11 tract is expected to compromise the role of hMRE11 in the maintenance of microsatellite stability (17). The reduction, but not abolition, of hMRE11 expression may be advantageous for tumor cells to maintain growth potential. Alternatively, reduction of hMRE11 protein expression by shortening of the poly(T)11 tract could impair the function of hMRE11 in DNA replication (42, 43), *i.e.* loosening damage surveillance at the replication fork, and as such increase the rate of replication slippage at microsatellite sequences. In short, the current literature suggests that hMRE11 is involved in the process of MMR and MMR-dependent tumorigenesis in colorectal cancers.

hMRE11 and telomere repeat stability

With approximately 3-20 kilobases of tandem hexanucleotide (TTAGGG)_n repeats, telomeres may conceptually be envisioned as super microsatellites (1). The functions of hMRE11 at telomeres are multifaceted, spanning from telomerase regulation and telomere ends processing to telomere DNA damage sensing. Telomere dysfunction directly contributes to genome stability. Defective MMR deregulates telomere length control and induces alternative lengthening of telomeres through telomeric DNA recombination (44). Through binding to TRF2, hMRE11 localizes to telomeres and maintains its stability (45, 46). During telomere DNA replication, hMRE11 protects newly replicated leading strand telomeres from the action of NHEJ by promoting end resection to generate single strand telomere overhangs, and cells lacking hMRE11 failed to activate DNA damage response induce by uncapped telomeres (46). However, the precise molecular mechanism underlying the involvement of hMRE11 in telomere protection remains to be elucidated.

Although telomere end metabolism is a unique molecular event (47, 48), the bulk of telomeres are most probably replicated similarly as the rest of chromosomal DNA. Replication of long microsatellite sequences such as telomeres is more prone to replication slippage. In sporadic colon cancers, telomeres were shortened in MSI positive tumors especially when hMSH2 was deficient (49, 50). Consistent with a role for hMSH2 in the regulation of telomere stability, hMSH2 silencing in normal human cells was shown to accelerate telomere shortening (51). Furthermore, hMSH2 also play a role in sensing telomere dysfunction, as abrogation of MSH2 eliminated DNA damage response normally triggered by short telomeres (52). In addition, several types of telomere repeat variants were found to be extremely prone to replication-dependent instability in somatic cells (53), implying that telomere instability may be more common than previous thought.

Albeit the biological significance of IDLs at telomeres has yet to be explored, one can envision that such aberrant structures are able to trigger DNA repair and damage responses. It is conceivable that hMRE11 may have a role in the maintenance of telomere repeat stability—a trait that can be difficult to analyze and it may require the development of more sensitive means. Nonetheless, altering hMRE11 function by poly(T)11 mutation is expected to increase telomere instability while decrease telomere damage response concomitantly. The combination of these two effects would likely facilitate the accumulation of genomic rearrangements in cancer cells. Further studies are warranted to determine the precise molecular mechanism of action and to elucidate the dynamic interplay between the hMRE11 complex and the MMR pathway in DNA damage surveillance and cancer development.

Summary and perspective

A better understanding of the pathogenic effects stemmed from MMR deficiency is essential for devising effective anti-cancer strategies. Identification of potential MMR target genes represents an important approach for reaching that goal. Increasing evidence indicates that hMRE11 is not a typical MMR target gene—reduction of hMRE11 protein level or the generation of hMRE11 truncation peptide might be one of the prime risk factors to trigger MMR deficiency in highly proliferative cell types such as colonic epithelial cells. The subtle functional changes of hMRE11, initiated from poly(T)11 deletion, in fast growing cells may increase the probability of replication slippage at microsatellite sequences and compromise MMR. To this end, it would be of great interest to delineate the temporal correlation between hMRE11 poly(T)11 mutation and MMR deficiency during cancer development. Given the important role that hMRE11 plays in cellular proliferation, perhaps a fraction of the wildtype poly(T)11 and/or 1 bp deletion alleles observed in various tumor types were

actually revertants of 1 bp or 2 bp deletion mutants—regaining hMRE11 function may help tumor cells to reach a full proliferation potential.

Acknowledgments

Work performed in the Her laboratory has been supported by grants from the National Institutes of Health (CA101796 and GM084353).

References

1. Ellegren H. Microsatellites: simple sequences with complex evolution. *Nat Rev Genet.* 2004; 5:435–45. [PubMed: 15153996]
2. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. *Science.* 1993; 260:812–6. [PubMed: 8484121]
3. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature.* 1993; 363:558–61. [PubMed: 8505985]
4. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science.* 1993; 260:816–9. [PubMed: 8484122]
5. Halford S, Sasieni P, Rowan A, Wasan H, Bodmer W, Talbot I, et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. *Cancer Res.* 2002; 62:53–7. [PubMed: 11782358]
6. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* 1998; 58:5248–57. [PubMed: 9823339]
7. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst.* 2004; 96:261–8. [PubMed: 14970275]
8. Lawes DA, SenGupta S, Boulos PB. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. *Eur J Surg Oncol.* 2003; 29:201–12. [PubMed: 12657227]
9. Genschel J, Littman SJ, Drummond JT, Modrich P. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. *J Biol Chem.* 1998; 273:19895–901. [PubMed: 9677427]
10. Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T, Jiricny J. hMutSbeta, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA. *Curr Biol.* 1996; 6:1181–4. [PubMed: 8805365]
11. Raschle M, Marra G, Nystrom-Lahti M, Schar P, Jiricny J. Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. *J Biol Chem.* 1999; 274:32368–75. [PubMed: 10542278]
12. Cannavo E, Marra G, Sabates-Bellver J, Menigatti M, Lipkin SM, Fischer F, et al. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. *Cancer Res.* 2005; 65:10759–66. [PubMed: 16322221]
13. Peltomaki P. Lynch syndrome genes. *Fam Cancer.* 2005; 4:227–32. [PubMed: 16136382]
14. Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLalpha in human mismatch repair. *Cell.* 2006; 126:297–308. [PubMed: 16873062]
15. Genschel J, Bazemore LR, Modrich P. Human exonuclease I is required for 5' and 3' mismatch repair. *J Biol Chem.* 2002; 277:13302–11. [PubMed: 11809771]
16. Wei K, Clark AB, Wong E, Kane MF, Mazur DJ, Parris T, et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. *Genes Dev.* 2003; 17:603–14. [PubMed: 12629043]
17. Vo AT, Zhu F, Wu X, Yuan F, Gao Y, Gu L, et al. hMRE11 deficiency leads to microsatellite instability and defective DNA mismatch repair. *EMBO Rep.* 2005; 6:438–44. [PubMed: 15864295]

18. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. *EMBO Rep.* 2002; 3:248–54. [PubMed: 11850399]
19. Ottini L, Falchetti M, Saieva C, De Marco M, Masala G, Zanna I, et al. MRE11 expression is impaired in gastric cancer with microsatellite instability. *Carcinogenesis.* 2004; 25:2337–43. [PubMed: 15319296]
20. Li HR, Shagisultanova EI, Yamashita K, Piao Z, Perucho M, Malkhosyan SR. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. *Cancer Res.* 2004; 64:4760–7. [PubMed: 15256444]
21. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, et al. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. *Oncogene.* 2004; 23:2640–7. [PubMed: 15048091]
22. Mongiat-Artus P, Miquel C, Van der Aa M, Buhard O, Hamelin R, Soliman H, et al. Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract. *Oncogene.* 2006; 25:2113–8. [PubMed: 16288216]
23. Ham MF, Takakuwa T, Luo WJ, Liu A, Horii A, Aozasa K. Impairment of double-strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia-lymphoma cell lines with microsatellite instability. *Cancer Sci.* 2006; 97:226–34. [PubMed: 16542220]
24. Alemayehu A, Fridrichova I. The MRE11/RAD50/NBS1 complex destabilization in Lynch-syndrome patients. *Eur J Hum Genet.* 2007; 15:922–9. [PubMed: 17534377]
25. Miquel C, Jacob S, Grandjouan S, Aime A, Viguier J, Sabourin JC, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. *Oncogene.* 2007; 26:5919–26. [PubMed: 17384679]
26. Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Joensuu EI, et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. *Carcinogenesis.* 2008; 29:1351–9. [PubMed: 18550572]
27. D'Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, et al. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. *Eur J Cancer.* 2009; 45:461–9. [PubMed: 19081245]
28. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. *Genes Dev.* 2000; 14:927–39. [PubMed: 10783165]
29. Her C, Vo AT, Wu X. Evidence for a direct association of hMRE11 with the human mismatch repair protein hMLH1. *DNA Repair (Amst).* 2002; 1:719–29. [PubMed: 12509276]
30. Mirzoeva OK, Kawaguchi T, Pieper RO. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. *Mol Cancer Ther.* 2006; 5:2757–66. [PubMed: 17121922]
31. Zhao N, Zhu F, Yuan F, Haick AK, Fukushima S, Gu L, et al. The interplay between hMLH1 and hMRE11: role in MMR and the effect of hMLH1 mutations. *Biochem Biophys Res Commun.* 2008; 370:338–43. [PubMed: 18373977]
32. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. *EMBO J.* 2003; 22:5612–21. [PubMed: 14532133]
33. Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavo E, et al. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. *EMBO J.* 2003; 22:2245–54. [PubMed: 12727890]
34. Rass E, Grabarz A, Plo I, Gautier J, Bertrand P, Lopez BS. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. *Nat Struct Mol Biol.* 2009; 16:819–24. [PubMed: 19633668]
35. Xie A, Kwok A, Scully R. Role of mammalian Mre11 in classical and alternative nonhomologous end joining. *Nat Struct Mol Biol.* 2009; 16:814–8. [PubMed: 19633669]
36. Siehler SY, Schrauder M, Gerischer U, Cantor S, Marra G, Wiesmuller L. Human MutL-complexes monitor homologous recombination independently of mismatch repair. *DNA Repair (Amst).* 2009; 8:242–52. [PubMed: 19022408]
37. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. *Chem Rev.* 2006; 106:302–23. [PubMed: 16464007]

38. Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. *Fam Cancer*. 2008; 7:41–52. [PubMed: 17636426]
39. van der Heijden MS, Brody JR, Elghalbzouri-Maghrani E, Zdzienicka MZ, Kern SE. Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. *BMC Genet*. 2006; 7:3. [PubMed: 16417627]
40. Kim NG, Choi YR, Baek MJ, Kim YH, Kang H, Kim NK, et al. Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability. *Cancer Res*. 2001; 61:36–8. [PubMed: 11196187]
41. Rodriguez R, Hansen LT, Phear G, Scorch J, Spang-Thomsen M, Cox A, et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. *Clin Cancer Res*. 2008; 14:5476–83. [PubMed: 18765539]
42. Mirzoeva OK, Petrini JH. DNA replication-dependent nuclear dynamics of the Mre11 complex. *Mol Cancer Res*. 2003; 1:207–18. [PubMed: 12556560]
43. Buis J, Wu Y, Deng Y, Leddon J, Westfield G, Eckersdorff M, et al. Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation. *Cell*. 2008; 135:85–96. [PubMed: 18854157]
44. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. *Cancer Res*. 2004; 64:3444–51. [PubMed: 15150096]
45. Zhu XD, Kuster B, Mann M, Petrini JH, de Lange T. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. *Nat Genet*. 2000; 25:347–52. [PubMed: 10888888]
46. Deng Y, Guo X, Ferguson DO, Chang S. Multiple roles for MRE11 at uncapped telomeres. *Nature*. 2009; 460:914–8. [PubMed: 19633651]
47. Blackburn EH. Switching and signaling at the telomere. *Cell*. 2001; 106:661–73. [PubMed: 11572773]
48. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev*. 2005; 19:2100–10. [PubMed: 16166375]
49. Pickett HA, Baird DM, Hoff-Olsen P, Meling GI, Rognum TO, Shaw J, et al. Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene. *Oncogene*. 2004; 23:3434–43. [PubMed: 15048084]
50. Takagi S, Kinouchi Y, Hiwatashi N, Nagashima F, Chida M, Takahashi S, et al. Relationship between microsatellite instability and telomere shortening in colorectal cancer. *Dis Colon Rectum*. 2000; 43:S12–7. [PubMed: 11052472]
51. Mendez-Bermudez A, Royle NJ. Deficiency in DNA mismatch repair increases the rate of telomere-shortening in normal human cells. *Hum Mutat*. 2011
52. Martinez P, Siegl-Cachedenier I, Flores JM, Blasco MA. MSH2 deficiency abolishes the anticancer and pro-aging activity of short telomeres. *Aging Cell*. 2009; 8:2–17. [PubMed: 18986375]
53. Mendez-Bermudez A, Hills M, Pickett HA, Phan AT, Mergny JL, Riou JF, et al. Human telomeres that contain (CTAGGG)_n repeats show replication dependent instability in somatic cells and the male germline. *Nucleic Acids Res*. 2009; 37:6225–38. [PubMed: 19656953]

Figure 1.

Model for the effect of hMRE11 IVS-4 poly(T)11 mutation on MSI and MMR. In MSS colonic cells, 1 bp deletion at the hMRE11 poly(T)11 tract randomly arises from replication slippage, resulting in subtle reduction of full-length hMRE11 expression and a slight increase of the truncated hMRE11 protein. These in turn lead to MSI and MMR gene inactivation in clonal expanded cells, thereby promoting subsequent MMR target gene mutations and tumorigenesis. In MSI colonic cells, 1 bp deletion at the hMRE11 poly(T)11 tract is readily accumulated and exerts its biological effects in a similar fashion as stated above, whereas 2 bp deletion at the poly(T)11 tract has a more direct effect on tumorigenesis.